BRIEF published on 09/24/2024 at 23:05, 1 year 4 months ago Theralase clôture un placement privé sans intermédiaire et émet des options sur actions Placement Privé Sans Intermédiaire Technologies Théralase Options Sur Actions Financement De La Recherche Clinique Étude Sur Le Cancer De La Vessie
BRIEF published on 09/24/2024 at 23:05, 1 year 4 months ago Theralase Closes Non-Brokered Private Placement and Issues Stock Options Stock Options Non-brokered Private Placement Theralase Technologies Clinical Research Funding Bladder Cancer Study
PRESS RELEASE published on 09/24/2024 at 23:00, 1 year 4 months ago Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options Theralase Technologies Inc. successfully closes Non-Brokered Private Placement offering of units for cancer research and development Private Placement Pharmaceutical Company Theralase Technologies Inc. Clinical Study Cancer Research
BRIEF published on 09/19/2024 at 23:10, 1 year 4 months ago Theralase® prolonge ses mandats Extension Bourse De Croissance TSX Technologies Théralase Bons De Souscription D'actions Développement Pharmaceutique
BRIEF published on 09/19/2024 at 23:10, 1 year 4 months ago Theralase® Extends Warrants Share Purchase Warrants TSXV Extension Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 09/19/2024 at 23:05, 1 year 4 months ago Theralase(R) Extends Warrants Theralase Technologies Inc. plans to extend expiry date of 10,000,000 share purchase warrants from Sept 22, 2024, to Sept 22, 2027. Warrants issued in 2022 at $0.35/share. TSXV approval pending TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 09/03/2024 at 13:05, 1 year 5 months ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Ruvidar Antiviral Drug HSV-1 Acyclovir
BRIEF published on 09/03/2024 at 13:05, 1 year 5 months ago Ruvidar(TM) s'avère plus efficace que l'acyclovir dans la destruction du virus de l'herpès simplex Theralase Ruvidar Médicament Antiviral HSV-1 Acyclovir
PRESS RELEASE published on 09/03/2024 at 13:00, 1 year 5 months ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Technologies Inc. announces preclinical superiority of Ruvidar TM in destroying HSV-1 virus, seeking partnerships for commercial development Theralase Technologies Inc. Preclinical Study Partnerships Ruvidar TM HSV-1 Virus
BRIEF published on 08/28/2024 at 13:05, 1 year 5 months ago Rutherrin® augmente l'efficacité de la chimiothérapie contre le cancer du poumon Theralase® Technologies Inc. Chimiothérapie CPNPC Rutherrine® Cisplatine
Published on 02/11/2026 at 14:35, 5 hours 17 minutes ago Worksport Delivers Breakout Q4: Revenue Up 65% YoY, Gross Profit Up 380%
Published on 02/11/2026 at 14:30, 5 hours 22 minutes ago Sekur Private Data CEO Updates on Growth, Market Expansion, Corporate Developments and New Product Launch
Published on 02/11/2026 at 14:00, 5 hours 52 minutes ago Organto Foods Inc. Expands Scalable and Flexible Logistics Platform to Support 2026 Growth
Published on 02/11/2026 at 14:00, 5 hours 52 minutes ago PPX Mining Provides Operational and Corporate Update
Published on 02/11/2026 at 14:00, 5 hours 52 minutes ago Meta Critical Minerals Engages Quad Consulting Group to Advance Table Mountain Silica Project Development Strategy
Published on 02/11/2026 at 18:31, 1 hour 20 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/11/2026 at 18:00, 1 hour 52 minutes ago Private Equity Holding AG: Net Asset Value as of January 31, 2026
Published on 02/11/2026 at 17:45, 2 hours 7 minutes ago Linedata Services: 2025 Annual Results - Revenue: €169.6 m (-7.7%) EBITDA margin: 22.1% of revenue
Published on 02/11/2026 at 17:45, 2 hours 7 minutes ago Linedata Services: Résultats annuels 2025 - Chiffre d’affaires : 169,6 M€ (-7,7%) Marge d’EBITDA : 22,1% du CA
Published on 02/11/2026 at 17:45, 2 hours 7 minutes ago Infotel : Stake held in AeroEx. A publisher of digital compliance and safety solutions for the aerospace industry.
Published on 02/11/2026 at 17:45, 2 hours 7 minutes ago Infotel : Prise de participation dans AeroEx éditeur de solutions digitales de conformité et de sécurité pour l’industrie aéronautique.
Published on 02/11/2026 at 11:25, 8 hours 26 minutes ago Innelec : Mise à disposition du rapport financier semestriel 2025-26
Published on 02/11/2026 at 08:00, 11 hours 52 minutes ago Imerys-press-release French State acquisition stake Emili Lithium
Published on 02/11/2026 at 08:00, 11 hours 52 minutes ago Imerys-communique-de-presse prise participation Etat Français Projet lithium Emili
